- Home
- CNTX vs ACHV Comparison
CNTX vs ACHV Comparison
Compare CNTX & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNTX | ACHV |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 209.5M | 233.7M |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | CNTX | ACHV |
|---|---|---|
| Price | $2.88 | $4.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 2 |
| Target Price | $6.00 | ★ $15.50 |
| AVG Volume (30 Days) | ★ 1.0M | 337.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 69.33 | 17.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.49 | $1.84 |
| 52 Week High | $3.30 | $6.03 |
Technical Indicators
Market Signals| Indicator | CNTX | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 65.86 | 44.01 |
| Support Level | $2.07 | $3.93 |
| Resistance Level | N/A | $4.30 |
| Average True Range (ATR) | 0.23 | 0.23 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 69.26 | 23.40 |
Price Performance
Historical ComparisonAbout CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.